OnKure Therapeutics (NASDAQ:OKUR) Posts Earnings Results, Beats Expectations By $0.05 EPS

OnKure Therapeutics (NASDAQ:OKUR) posted its earnings results on Wednesday. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.05, FiscalAI reports.

OnKure Therapeutics Price Performance

Shares of NASDAQ:OKUR traded up $0.09 on Wednesday, reaching $2.59. The company’s stock had a trading volume of 876,952 shares, compared to its average volume of 332,770. The stock’s 50-day moving average is $2.83 and its two-hundred day moving average is $3.59. OnKure Therapeutics has a 52-week low of $2.01 and a 52-week high of $5.38.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on OKUR. Oppenheimer restated an “outperform” rating and set a $14.00 price target on shares of OnKure Therapeutics in a research note on Friday, August 14th. Weiss Ratings raised OnKure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, October 26th. Finally, HC Wainwright reduced their price objective on OnKure Therapeutics to $21.00 and set a “buy” rating for the company in a research note on Monday, July 20th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, OnKure Therapeutics has an average rating of “Hold” and an average price target of $17.50.

About OnKure Therapeutics

OnKure Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company’s research is centered on small-molecule therapies designed to target cancer-driving transcription factors and related proteins that are difficult to address with conventional drug approaches.

Its lead product candidate, OKN4395, is an oral small-molecule inhibitor of the EP300/CBP bromodomains. The program is being investigated as a potential treatment for solid tumors, including in combination with immune checkpoint inhibitors such as pembrolizumab.